B
Biosplice Therapeutics
Biotech & Life Sciences · San Diego, United States · Founded 2008 Decacorn
Investors
10 investors on Biosplice Therapeutics's cap table
Sourced from Dealroom's funding history.
Ownership
Who owns Biosplice Therapeutics
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Global footprint
Where Biosplice Therapeutics has talent and traffic
team presence
across markets
Talent graph
The shape of Biosplice Therapeutics's talent
Dealroom maps Biosplice Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$171M patent portfolio · 71 active families
Where Biosplice Therapeutics concentrates vs peers
Each axis is a top-10 topic across Biosplice Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Biosplice Therapeutics
An AI-synthesized read of the highest-engagement posts about Biosplice Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biosplice Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.